SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $604,294,540 |
| Positions | 59 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ANTERIS TECHNOLOGIES GLOBAL | AVR | COM | $54,627,942 | 5,545,984 |
| CENCORA INC | COR | COM | $49,121,932 | 173,588 |
| MAXIMUS INC | MMS | COM | $38,452,754 | 715,267 |
| ALLOGENE THERAPEUTICS INC | ALLO | COM | $27,712,736 | 13,323,431 |
| GLOBUS MED INC | GMED | CL A | $23,846,482 | 301,816 |
| GSK PLC | GSK | SPONSORED ADR | $22,891,814 | 436,700 |
| TYRA BIOSCIENCES INC | TYRA | COM | $22,208,361 | 695,315 |
| WAYSTAR HLDG CORP | WAY | COM | $19,007,372 | 925,834 |
| SELLAS LIFE SCIENCES GROUP I | SLS | COM NEW | $18,165,132 | 1,230,700 |
| IDEAYA BIOSCIENCES INC | IDYA | COM | $17,903,874 | 480,383 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.